Work

Preclinical and phase 1/2 data of the CHK1 inhibitor BBI-355 in development for esophageal and gastric cancers (EGC) with EGFR or FGFR2 amplifications.

Year: 2025

Type: article

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.4_suppl.tps517

Authors: Steven Brad Maron, Manish R Sharma, Alexander I. Spira, Ildefonso I Rodriguez Rivera, Sant P. Chawla, Alexander Philipovskiy, Melissa Lynne Johnson, Gerald Steven Falchook, Zev A. Wainberg, Ryan Hansen, Sara Weymer, Klaus Wagner, Timothy A. Yap

Institutions: Memorial Sloan Kettering Cancer Center, Virginia Cancer Specialists, Sarcoma Oncology Center, Florida Cancer Specialists & Research Institute, Sarah Cannon, HealthONE, University of California, Los Angeles, Boundless Bio (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4406870908

FWCI: 3.57

Cites:

Cited by: 4

Related to: 10